Aprea Therapeutics (APRE) Other Non-Current Assets (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Other Non-Current Assets of $271162.0 for Q1 2026, little changed year-over-year from $271162.0 in Q1 2025, and little changed quarter-over-quarter from $271162.0 in Q4 2025.
Aprea Therapeutics (APRE) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Other Non-Current Assets for 9 consecutive years, with $271162.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $271162.0; the TTM figure through Mar 2026 stood at $271162.0 (changed 0.0% YoY), while the FY2025 annual figure was $271162.0, down 3.73% from the prior year.
- Other Non-Current Assets was little changed at $271162.0 in Q1 2026 per APRE's latest filing, from $271162.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $281662.0 in Q4 2024 and bottomed at $29351.0 in Q3 2022.
- Historically, Other Non-Current Assets has averaged $116012.7 across 5 years, with a median of $40986.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 591.76% — and 2025, when it retreated 3.73%.
- Aprea Therapeutics' Other Non-Current Assets stood at $29351.0 in 2022, then jumped by 38.72% to $40717.0 in 2023, then surged by 591.76% to $281662.0 in 2024, then fell by 3.73% to $271162.0 in 2025, then changed by 0.0% to $271162.0 in 2026.
- Business Quant data shows APRE's Other Non-Current Assets at $271162.0 in Q1 2026, $271162.0 in Q4 2025, and $271162.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | 271,162.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 271,162.00 |
| Mar 31, 2026 | 271,162.00 |
| Dec 31, 2025 | 271,162.00 |
| Sep 30, 2025 | 271,162.00 |
| Jun 30, 2025 | 40,673.00 |
| Mar 31, 2025 | 271,162.00 |
| Dec 31, 2024 | 281,662.00 |
| Sep 30, 2024 | 41,537.00 |
| Jun 30, 2024 | 41,260.00 |
| Mar 31, 2024 | 40,986.00 |
| Dec 31, 2023 | 40,717.00 |
| Sep 30, 2023 | 40,449.00 |
| Jun 30, 2023 | 40,180.00 |
| Sep 30, 2022 | 29,351.00 |
| Jun 30, 2022 | 29,359.00 |
| Mar 31, 2022 | 29,369.00 |
| Dec 31, 2021 | 29,372.00 |
| Sep 30, 2021 | 29,375.00 |
| Jun 30, 2021 | 29,379.00 |
| Mar 31, 2021 | 29,376.00 |